Relationship of B12 status measures with outcomes in SURE-PD2, SURE-PD3 and STEADY-PD III Michael J Fox Foundation for Parkinson's Research 18462Sep 30, 2020 - Aug 30, 2022 Role: PI Description: To determine whether vitamin B12 and other B12 status measures are associated with PD progression using plasma specimens from recently performed clinical trial of early PD progression |
Open-Label Safety Study of Glial cell Line derived neurotrophic factor Gene transfer (AAV2-GDNF) in Parkinson’s disease Brain Neurotherapy Bio, Inc Aug 1, 2020 - Apr 30, 2026 Role: Site Co-PI Description: To determine the safety and possible clinical benefits of this treatment in PD. |
NLY01-PD-1Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease Neuraly, Inc Apr 1, 2020 - Dec 31, 2021 Role: Site Investigator Description: To determine the safety and possible benefit of NLY01-PD in early PD |
PD 1105: A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson’s Disease Patients with Motor Fluctuations Neurocrine Biosciences, Inc Nov 1, 2018 - Dec 31, 2023 Role: Site PI Description: To determine the safty and efficacy of VY-AADC02 in subjects with advanced PD |
PD 1104: An Observational, Long-Term Extension Study for Participants of Prior VY-AADC01 or VY-AADC02 Clinical Studies Neurocrine Biosciences, Inc Apr 1, 2018 - Dec 31, 2029 Role: Site PI Description: To provide long term observational follow-up of subjects treated with AADC gene therapy |
PD 1102: An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion using a Posterior Trajectory into the Putamen of Participants with Parkinson’s Disease with fluctuating Responses to Levodopa. Voyager Therapeutics Jan 1, 2017 - Apr 30, 2021 Role: Site Co-PI Description: To determine the safety and possible clinical benefit of VY-AADC01 in moderately advanced Parkinson's disease |
Relationship of cerebrospinal markers of B12 status to baseline status and outcomes in the DATATOP study NIH and Michael J Fox Foundation for Parkinson's Research 11951May 1, 2016 - Jun 30, 2019 Role: PI Description: To determine whether cerebrospinal markers of B12 status are associated with PD progression. |
“A Phase 3 double-blind placebo-controlled parallel group study of isradipine as a disease modifying agent in patients with early Parkinson disease.” NIH Jul 1, 2014 - Nov 30, 2015 Role: Site PI Description: To determine whether isradipine haa a disease modifying effect on PD progression |
The Relationship of Vitamin B12 status and Parkinson’s disease Michael J Fox Foundation for Parkinson's Research 8646Jan 1, 2014 - Mar 30, 2015 Role: PI Description: To Study the association of vitamin B12 and homocysteine levels with PD progression using serum samples from the DATATOP study of early Parkinson's disease. |
Parkinson's Disease Neuroprotection Clinical Trial NIH U10NS044460Sep 15, 2002 - Nov 30, 2015 Role: Co-PI Description: To determine the safety and possible clinical benefit of AADC gene therapy in moderately advance PD. |
MECHANISMS UNDERLYING HOMOSYNAPTIC LONG TERM DEPRESSION NIH K08NS001813Jul 1, 1995 - May 31, 2000 Role: Principal Investigator |